Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A pioneering academic conference will bring together, for the first time, people from all over the world dealing with the problem of poor quality medicines and their impact on public health. The Medicine Quality & Public Health conference will take place at Keble College, Oxford, 23-28 Sept 2018. It will provide a unique opportunity for health authorities, scientists, pharmacists, lawyers and international organisations to discuss the problem and outline the necessary steps to tackle the issue on a global scale.

Pills

The proliferation of poor quality medicines is an important but neglected public health problem, threatening millions of people all over the world, both in developing and wealthy countries. Although – rightly - there has been much attention to improving access to affordable medicines, there has been less emphasis on ensuring that they are good quality or not altogether falsified.

“All over the world, medicines regulatory authorities, research groups, international organisations, law enforcement agencies and other key stakeholders, including the pharmaceutical industry, are working hard to keep patients safe and to try to ensure that the benefits of modern medicine are delivered,” says Prof Paul Newton, Head of the Medicine Quality Group at the Infectious Diseases Data Observatory (IDDO), Director of the Oxford clinical research unit in Laos and the instigator of the conference.

“However, there has never been an opportunity for the diverse stakeholders involved in medicine quality and drug regulation to come together within the framework of a dedicated academic conference to share ideas and expertise. One of the event’s key objectives is to develop a consensus statement to be widely disseminated to interested parties and policy makers, establishing the conference as a turning point in our collective approach to tackling poor quality medicines.”

The conference was inspired by a successful multidisciplinary annual course on the Quality of Medical Products & Public Health, which has been held since 2015 at the London School of Hygiene & Tropical Medicine and Boston University. This year the course and conference will run sequentially, allowing participants to combine in-depth training with networking and scientific discussion.

Discounts and fellowships are available for participants from low- and middle-income countries.

If you are interested in attending the conference tickets are nearly sold out, please visit the conference website or email mqph2018@ndm.ox.ac.uk.

Similar stories

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

FIEBRE Laos concludes recruitment

Congratulations to everyone involved in contributing to FIEBRE’s success - the clinical and laboratory staff, hospital, participants and local communities. The team has continued working throughout the COVID-19 epidemic despite national restrictions which slowed down enrolment and limited field activities.

Congratulations new NDM professors

The University of Oxford has awarded CTMGH two new Professors. Elisabeth Ashley - UK-trained physician who specialises in infectious diseases and medical microbiology & virology, and Director of the Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit (LOMWRU) in Lao PDR since 2019, Liz is conferred the title of Professor of Tropical Medicine. Stuart Blacksell - Senior Research Scientist based at the Mahidol-Oxford Tropical Medicine Research Unit (MORU) in Thailand, Stuart is conferred the title of Professor of Tropical Microbiology.

Large scale systematic review details causes of non-malarial febrile illnesses globally and identifies research priorities

A series of articles that set out to explore the global distribution of infections that cause non-malarial febrile illness has been published in BMC Medicine. The series brings together the results of large-scale systematic reviews of the causes of fever in Africa, Latin America, and Southern and South-Eastern Asia, and has helped identify major knowledge gaps, geographical differences, priority areas for diagnostics research and development, and enabled the most comprehensive systematic review of literature to date.

Professor Paul Newton wins the Helen Clark-JoPPP Award

We are delighted to announce that Professor Paul Newton has won the Helen-Clark-JoPPP Award for Pharmaceutical Policy and Practice Research. This award is based on the scientific merit of his work, as well as its impact on patients, decisions makers, and on governments. It recognizes the talents of exceptional researchers who are making a significant contribution to the field of pharmaceutical policy and practice.